VIRX (Viracta Therapeutics) Pretax Margin %: % (As of Sep. 2024)


What is Viracta Therapeutics Pretax Margin %?

Viracta Therapeutics VIRX Pretax Margin % is % as of Sep. 2024.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Viracta Therapeutics's Pre-Tax Income for the three months ended in Sep. 2024 was $-10.55 Mil. Viracta Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Viracta Therapeutics's pretax margin for the quarter that ended in Sep. 2024 was %.

The historical rank and industry rank for Viracta Therapeutics's Pretax Margin % or its related term are showing as below:


VIRX's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.5
* Ranked among companies with meaningful Pretax Margin % only.

Viracta Therapeutics  (OTCPK:VIRX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Viracta Therapeutics Pretax Margin % Related Terms

Viracta Therapeutics Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Viracta Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viracta Therapeutics Pretax Margin % Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Pretax Margin %
0.00 0.00 0.00 0.00

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

VIRX vs TSOI, CYTOF, TRVN: Pretax Margin % Comparison

For the Biotechnology subindustry, Viracta Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viracta Therapeutics Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Viracta Therapeutics's Pretax Margin % falls into.


Viracta Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Viracta Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-51.058/0
= %

Viracta Therapeutics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-10.553/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
Viracta Therapeutics (VIRX) has a Pretax Margin % of % as of Sep. 2024. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Viracta Therapeutics and its competitors.
Is Viracta Therapeutics' Pretax Margin % too high?
Viracta Therapeutics' current Pretax Margin % is %.
How does Viracta Therapeutics' Pretax Margin % compare to TSOI and CYTOF?
Viracta Therapeutics' Pretax Margin % of % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Viracta Therapeutics and its competitors. Viracta Therapeutics's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viracta Therapeutics stock overvalued right now?
Viracta Therapeutics (VIRX) has a current Pretax Margin % of %. The current Pretax Margin % is %. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Viracta Therapeutics (VIRX), the current Pretax Margin % is % as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viracta Therapeutics Business Description

Address 2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.